Experimental labour-offshoring clinical trials to China

East Asian Science, Technology and Society

Volumn 2, Issue 1, 2008, Pages 73-92

  Cooper, Melinda ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

China; Clinical labour; Clinical trials; Contract research organization; Neoliberalism

Indexed keywords

EID: 72149131729     PISSN: 18752160     EISSN: 18752152     Source Type: Journal    
DOI: 10.1007/s12280-008-9040-y     Document Type: Article

References (50)

1. Anagnost, A. S. (2006). Strange circulations: The blood economy in rural China. Economy and Society, 35(4), 509-529.
2. Anderson, D. L. (2007). International patient recruitment: Regulatory guidelines, customs and practices. Dallas, TX: D. L. Anderson International Publishing.
3. Ashish, A., & Gambardella, A. (1994). The changing technology of technological change: General and abstract knowledge and the division of innovative labour. Research Policy, 23, 523-532.
4. Bailey, W., Cruickshank, C., & Sharma, N. (2007). Make your move: Taking clinical trials to the best location. http://www. atkearney.com/main.taf?p=5,1,1,116,3,1. Consulted March 2007.
5. Berton, E. (2006). More chinese get free drugs in clinical trials. Wall Street Journal Online, February 14. http://online. wsj. com/public/article/SB113988758015373215-3cIaQCU2VMtRObREr8e5Rj8AiP8_20060221.html. Accessed May 2007.
6. Blumenthal, D., & Hsiao, W. (2005). Privatization and its discontents-The evolving chinese health care system. New England Journal of Medicine, 353, 1165-1170.
7. Chigwedere, E. (2006). How much are we reporting about ethical misconduct: A critical review of Cyranowski's article 'Chinese Clinical Trials: Consenting adults? Not necessarily'. In Medical humanities report. Winter http:www.bioethics. msu.edu/mhr/06w/Ethical%20Misconduct.htm. Consulted March 2008.
8. Code of Federal Regulations 21, part 50, 44, 'Restrictions on clinical investigations involving prisoners.'.
9. Cooper, M., & Waldby, C. (2008). Clinical labour: Donors and research subjects in the bioeconomy. Unpublished manuscript.
10. Cyranowski, D. (2005). Consenting adults? Not necessarily...' Nature, 435, 138-139.
11. Dosi, G., & Mazzucato, M. (2006). Introduction. In G. Dosi & M. Mazzucato (Eds.), Knowledge accumulation and industry evolution: The case of pharma-biotech (pp. 1-18). Cambridge: Cambridge University Press.
12. Dutton, M. R. (2004). Streetlife China. New York and London: Routledge.
13. Epstein, S. (2007). Inclusion: The politics of difference in medical research. Chicago: The University of Chicago Press.
14. Ernst & Young (2006). Progressions 2006: Capturing global advantage in the pharmaceutical industry. New York: Ernst and Young Global Pharmaceutical Centre.
15. Fisher, J. A. (2007). Coming soon to a physician near you: Medical neoliberalism and pharmaceutical clinical trials. Harvard Health Policy Review, 8(1), 46-55.
16. Gambardella, A. (1995). Science and innovation in the US pharmaceutical industry. Cambridge: Cambridge University Press.
17. Goodall, S., Jannsens, B., Wagner, K., Wong, J., Woods, W., & Yeh, M. (2006). The promise of the east: India and China as R& D options. Nature Biotechnology, 24(9), 1061-1064.
18. Greenalgh, S., & Winkler, E. A. (2005). Governing China's population: From leninist to neoliberal biopolitics. Stanford, CA: Stanford University Press.
19. Hornblum, A. M. (1998). Acres of skin: Human experiments in Holmesburg prison. New York and London: Routledge.
20. Humphries, M., Niese, D., & Dai, P. (2006). China as a growing research base for innovation in medicines development. International Journal of Pharmaceutical Medicine, 20(6), 355-359.
21. Jia, H. (2005). China beckons to clinical trial sponsors. Nature Biotechnology, 23, 768.
22. Kearney, A. T. (Consulting Group) (2006). Fishing for opportunities: Successful clinical trials management. Pharmaceutical executive, June 1. http://www. pharmexec. com/pharmexec/article/articleDetail. jsp?id=333301. Consulted March 2007.
23. Krohn, W., & Weyer, J. (1994). Real life experiments-society as a laboratory: The social risks of experimental research. Science and Public Policy, 21(3), 173-183.
24. Lazzarato, M. (2002). Puissances de l'invention: La psychologie economique de Gabriel Tarde contre l'economie politique. Paris: Les empecheurs de penser en rond.
25. Mirowski, P., & van Horn, R. (2005). The contract research organization and the commercialization of scientific research. Social Studies of Science, 35(4), 503-548.
26. Morioka, J. (2006). Clinical trials in China: Today and tomorrow. Contract Services Europe 1, 20-22 (May).
27. Nightingale, P., & Mahdi, S. (2006). The evolution in pharmaceutical innovation. In G. Dosi & M. Mazzucato (Eds.), Knowledge accumulation and industry evolution: The case of pharma-biotech (pp. 73-111). Cambridge: Cambridge University Press.
28. Ong, A. (2007). Neoliberalism as exception: Mutations in citizenship and sovereignty. Durham: Duke University Press.
29. Petryna, A. (2006). Globalizing human subjects research. In A. Petryna, A. Lakoff, & A. Kleinman (Eds.), Global pharmaceuticals: Ethics, markets, practices (pp. 33-60). Durham: Duke University Press.
30. Petryna, A. (2007). Clinical trials offshored: On private sector science and public health. BioSocieties, 2, 21-40.
31. Pisano, G. P. (2006). Science business: The promise, the reality, and the future of biotech. Boston, MA: Harvard Business School Press.
32. Reid, R. G. B. (2007). Biological emergences: Evolution by natural experiment. London: MIT Press.
33. Rheinberger, H.-J. (1997). Experimental complexity in biology: Some epistemological and historical remarks. Philosophy of Science, 64(Supplement), S245-S254 (December).
34. Ross, A. (2006). Fast boat to China: Corporate flight and the consequences of free trade; Lessons from Shanghai. New York: Pantheon.
35. Salter, B., Cooper, M., & Dickins, A. (2006). China and the global stem cell bioeconomy: An emerging political strategy? Regenerative Medicine, 1(5), 671-683.
36. Salter, B., Cooper, M., Dickins, A., & Cardo, V. (2007). Stem cell science in India: Emerging economies and the politics of globalisation. Regenerative Medicine, 2(1), 75-89.
37. Sassen, S. (2003). Global cities and survival circuits. In B. Ehrenreich & A. Hothschild (Eds), Global woman: Nannies, maids and sex workers in the new economy. London: Granta Books.
38. Sharma, S. (2004). Remembering SARS in Beijing: The nationalist appropriation of an epidemic. Sarai Reader, 4, 332-339.
39. Shuchman, M. (2007). Commercializing clinical trials-risks and benefits of the CRO boom. The New England Journal of Medicine, 357(14), 1365-1368.
40. Sunder Rajan, K. (2006). Biocapital-the constitution of postgenomic life. Durham: Duke University Press.
41. Sunder Rajan, K. (2007). Experimental values: Indian clinical trials and surplus health. New Left Review, 45, 67-78 (May-June).
42. Thiers, F. A., Sinskey, A. J., & Berndt, E. R. (2008). Trends in the globalization of clinical trials. Nature Reviews Drug Discovery, 7, 13-14 (January).
43. Thomas Scott, C., & Baker, M. (2007). Overhauling clinical trials. Nature Biotechnology, 25(3), 287-292.
44. Thomke, S., von Hippel, E., & Franke, R. (1998). Modes of experimentation: An innovation process-and competitive-variable. Research Policy, 27, 315-332.
45. Thomson CenterWatch. (2007). State of the clinical trials industry: A sourcebook of charts and statistics. Boston: Thomson CenterWatch.
46. Vaidya, A., Anastasia, L., & Kermani, F. (2007). The chinese biotechnology, life science and pharmaceutical industry (UK trade and investment life sciences sector group). London: UK Trade and Investment.
47. Vastag, B. (2006). New clinical trials policy at FDA. Nature Biotechnology, 24(9), 1043.
48. Waldby, C., & Cooper, M. (2008). Post-fordist biotechnology and women's clinical labour. Australian Feminist Studies, 23(55), 57-73.
49. Watts, J. (2007). Chinese hospital staff face attacks amid high prices and dubious care. The Guardian (12 May).
50. Xu, J., Li, B., Qiang, M., Liu, H., & Cong, Y. (2006). Human subjects protections in clinical drug trials in China: A focus on the institute level. International Journal of Pharmaceutical Medicine, 20(6), 367-372.